Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [119].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“there was no significant difference in the 5-year survival rate”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group.”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Hyams, D. M., Mamounas, E. P., Petrelli, N., Rockette, H., Jones, J., Wieand, S. H., Deutsch, M., Wickerham, L. D., Fisher, B., & Wolmark, N. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02054976 · Cited by 360
Research works printed but not linked: 3
- Seegenschmiedt MH, 1993, Strahlenther Onkol, 169, 83
- Pichlmaier H, 1994, Chirurg, 65, 411
- Hermanek P. What can the pathologist tell the surgeon about rectal cancer resection? In: Scholefield JH, ed. Challenges in colorectal cancer. Oxford, England: Blackwell, 2000:81-90.
Cited by
Items 801–900 of 1,004
Rullier, A., Gourgou-Bourgade, S., Jarlier, M., Bibeau, F., Chassagne‐Clément, C., Hennequin, C., Tisseau, L., Leroux, A., Ettore, F., Péoc’h, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.028 · Cited by 59
Neo-adjuvant radiotherapy in rectal cancer
Glimelius, B. L. G. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i46.8489 · Cited by 71
Krauthamer, M., Rouvinov, K., Ariad, S., Man, S., Walfisch, S., Pinsk, I., Sztarker, I., Charkovsky, T., & Lavrenkov, K. (2013) · Oncology · doi:10.1159/000348385 · Cited by 67
Rectal cancer: Neoadjuvant chemoradiotherapy
Rödel, C. M., Hofheinz, R., & Fokas, E. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.06.004 · Cited by 63
“In that context, the Timing of Rectal Cancer Response to Chemoradiation Consortium in the United States conducted a prospective phase II trial of preoperative CRT (50.4 – 54 Gy with 225 mg/m²/day continuous infusion 5-FU during RT) and delayed the time point of surgery (Fig.”
BackgroundInfluentialSelf-citationMultiple treatment lines and prognosis in metastatic colorectal cancer patients
Carlomagno, C., Stefano, A. D., Rosanova, M., Falco, S. D., Attademo, L., Fiore, G., & Placido, S. D. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9748-7 · Cited by 62
Pucciarelli, S., Bianco, P. D., Toppan, P., Serpentini, S., Efficace, F., Pasetto, L. M., Friso, M. L., Salvo, G. L. D., & Nitti, D. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9923-0 · Cited by 59
García, V. M., Cejas, P., Codesido, M. B., Batlle, J. F., de Castro, J., Belda-Iniesta, C., Barriuso, J., Sánchez, J. J., Larrauri, J., González‐Barón, M., et al. (2009) · International Journal of Colorectal Disease · doi:10.1007/s00384-009-0682-6 · Cited by 57
“Median distance from anal verge [range], cm 5 [0–15]”
BackgroundInfluentialNapolitano, M., D’Alterio, C., Cardone, E., Trotta, A. M., Pecori, B., Rega, D., Pace, U., Scala, D., Scognamiglio, G., Tatangelo, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3014 · Cited by 59
Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer
Conde-Muíño, R., Cuadros, M., Zambudio, N., Segura-Jiménez, I., Cano, C., & Palma, P. (2015) · BioMed Research International · doi:10.1155/2015/921435 · Cited by 57
“The ideal treatment recommendations for rectal cancer are under permanent appraisal; nevertheless, studies have demonstrated that, for locally advanced rectal cancer (LARC) (stage T3, stage T4, or node-positive disease), preoperative (neoadjuvant) chemoradiation (CRT) significantly improves local control and reduces t…”
BackgroundWu, X.-R., Kiran, R. P., Remzi, F. H., Katz, S., Mukewar, S. S., & Shen, B. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.01.017 · Cited by 60
Coco, C., Rizzo, G., Mattana, C., Gambacorta, M. A., Verbo, A., Barbaro, B., Vecchio, F. M., Pafundi, D. P., Mastromarino, M. G., & Valentini, V. (2013) · Surgical Endoscopy · doi:10.1007/s00464-013-2842-6 · Cited by 58
“by total mesorectal excision (TME) as the ‘‘gold standard’’ for the treatment of locally advanced rectal cancer [1, 2].”
BackgroundTiv, M., Puyraveau, M., Mineur, L., Calais, G., Maingon, P., Bardet, É., Mercier, M., & Bosset, J.-F. (2010) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2010.06.017 · Cited by 58
Wong, R. K. S., Berry, S., Spithoff, K., Simunovic, M. R. I., Chan, K., Agboola, O., & Dingle, B. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.03.002 · Cited by 63
A Novel Risk-Adjusted Nomogram for Rectal Cancer Surgery Outcomes
Russell, M. C., You, Y. N., Hu, C., Cormier, J. N., Feig, B. W., Skibber, J. M., Rodríguez-Bigas, M. A., Nelson, H. D., & Chang, G. J. (2013) · JAMA Surgery · doi:10.1001/jamasurg.2013.2136 · Cited by 62
Does a Rectal Cancer of the Upper Third Behave More Like a Colon or a Rectal Cancer?
Rosenberg, R., Maak, M., Schuster, T., Becker, K., Friess, H., & Gertler, R. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181cdb25a · Cited by 61
“E-mail: Rosenberg@chir.med.tu-muenchen.de Dis Colon Rectum 2010; 53: 761–770 DOI: 10.1007/DCR.0b013e3181cdb25a ©The ASCRS 2010 DISEASES OF THE COLON & RECTUM VOLUME 53: 5 (2010) 761 against Cancer (UICC) stage II and III.9,11 These results led to the widely accepted recommendation that rectal cancers with UICC stage I…”
BackgroundInfluentialKalady, M. F., Mantyh, C. R., Petrofski, J. A., & Ludwig, K. A. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0510-2 · Cited by 57
Maximizing Rectal Cancer Results: TEM and TATA Techniques to Expand Sphincter Preservation
Marks, J. H., Frenkel, J. L., D’Andrea, A. P., & Greenleaf, C. E. (2011) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2011.01.008 · Cited by 60
Adjuvant treatment of colorectal cancer.
Carrato, A. (2008) · PubMed · Cited by 86
Qin, Q., Huang, B., Cao, W., Zhou, J., Ma, T., Zhou, Z., Wang, J., & Wang, L. (2017) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000801 · Cited by 62
Fazeli, M. S., & Keramati, M. R. (2015) · PubMed Central · Cited by 100
Advanced nanomaterials targeting hypoxia to enhance radiotherapy
Li, J., Shang, W., Li, Y., Fu, S., Tian, J., & Lu, L. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s173914 · Cited by 58
MRI of rectal cancer—relevant anatomy and staging key points
Santiago, I., Figueiredo, N., Parés, O., & Matos, C. (2020) · Insights into Imaging · doi:10.1186/s13244-020-00890-7 · Cited by 62
Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions
Monga, D. K., & O’Connell, M. J. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.08.015 · Cited by 60
“The direct comparison of preoperative versus postoperative chemoradiation for clinically resectable cancers was attempted in three randomized controlled trials.(60,61) The two trials conducted in the United States (Intergroup 0147 and NSABP R-03) underwent early closure secondary to poor accrual.”
Short-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer: Making Progress
Minsky, B. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0551 · Cited by 61
Strous, M. T. A., Janssen-Heijnen, M. L. G., & Vogelaar, F. J. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.07.009 · Cited by 56
The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
Body, A. L., Prenen, H., Latham, S., Lam, M., Tipping-Smith, S., Raghunath, A., & Segelov, E. (2021) · Cancer Management and Research · doi:10.2147/cmar.s262870 · Cited by 61
Sato, T., Ozawa, H., Hatate, K., Onosato, W., Naito, M., Nakamura, T., Ihara, A., Koizumi, W., Hayakawa, K., Okayasu, I., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.11.007 · Cited by 62
Huh, J. W., Lee, J. H., & Kim, H. R. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31829b3916 · Cited by 56
Spigel, D. R., Bendell, J. C., McCleod, M., Shipley, D. L., Arrowsmith, E. R., Barnes, E. K., Infante, J. R., Burris, H. A., Greco, F. A., & Hainsworth, J. D. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.04.002 · Cited by 57
Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer
Grimminger, P., Danenberg, P. V., Dellas, K., Arnold, D., Rödel, C. M., Machiels, J., Haustermans, K. M., Debucquoy, A., Velenik, V., Sempoux, C. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2273 · Cited by 58
Self-citationKuo, Y.-C., Lin, W., Chiang, I., Chang, Y.-F., Chen, C.-W., Su, S.-H., Chen, C.-L., & Hwang, J. (2011) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.09.011 · Cited by 56
Fitzgerald, T. L., Brinkley, J., & Zervos, E. E. (2011) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2011.07.020 · Cited by 56
Landry, J. C., Feng, Y., Cohen, S. J., Staley, C. A., Whittington, R., Sigurdson, E. R., Nimeiri, H. S., Verma, U. N., Prabhu, R. S., & Benson, A. B. (2013) · Cancer · doi:10.1002/cncr.27890 · Cited by 59
“Neoadjuvant 5-FU–based CRT has become the standard of care for stage II to III rectal cancer in the United States due to the findings of improved local control, higher rates of sphincter-sparing procedures, and reduced toxicity versus adjuvant CRT, from the German Rectal Cancer Study Group phase 3 trial.(4) Capecitabi…”
BackgroundTan, B. R., Thomas, F., Myerson, R. J., Zehnbauer, B. A., Trinkaus, K. M., Malyapa, R. S., Mutch, M. G., Abbey, E. E., Alyasiry, A., Fleshman, J. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3212 · Cited by 58
“Thirty percent of patients experienced grade 3 to 4 toxicities, also comparable to that reported by Sauer et al(2) for preoperative FUbased CRT.(2) On the basis of previous published results,(27) we hypothesized that patients homozygous for the TSER*3 allele would only have a tumor DS rate of 22% with standard neoadju…”
BackgroundResultInfluentialPeng, J., Ding, Y., Tu, S., Shi, D., Sun, L., Li, X., Wu, H., & Cai, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106344 · Cited by 61
“However, the benefit of adjuvant chemotherapy after combined treatment of rectal cancer is still not well defined in single randomized trials [4,19,21].”
BackgroundSong, J. H., Jeong, J. U., Lee, J. H., Kim, S. H., Cho, H., Um, J. W., & Jang, H. S. (2017) · Radiation Oncology Journal · doi:10.3857/roj.2017.00059 · Cited by 62
“Preoperative or postoperative CRT in rectal cancer have been proven to reduce local and systemic recurrences than radiation or chemotherapy alone in randomized controlled trials [3,4], and more favorable results in locoregional control and sphincter preservation for preoperative CRT than for postoperative CRT had been…”
BackgroundMethodResultInfluentialColorectal liver metastases contract centripetally with a response to chemotherapy
Ng, J. K. S., Urbanski, S. J., Mangat, N. S., McKay, A. M., Sutherland, F. R., Dixon, E., Dowden, S. D., Ernst, S., & Bathe, O. F. (2007) · Cancer · doi:10.1002/cncr.23184 · Cited by 56
Wu, X., Zhang, J., He, X., Wang, C., Lian, L., Liu, H., Wang, J., & Lan, P. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1682-8 · Cited by 64
Temple, L. K. F., Romanus, D., Niland, J. C., ter Veer, A., Weiser, M. R., Skibber, J. M., Wilson, J. L., Rajput, A., Benson, A. B., Wong, Y. N., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181ae330e · Cited by 58
“Patients diverted with ileostomy or colostomy pre-SPS, and/or at the time of SPS, were considered to have undergone SPS. SPS procedures included low anterior resection or proctectomy with coloanal anastomosis (defined by the surgeon, and included either a stapled or hand-sewn anastomosis); non-SPS procedures included…”
BackgroundInfluentialDeorukhkar, A., Ahuja, N., Mercado, A. Y. C., Diagaradjane, P., Raju, U., Patel, N. B., Mohindra, P., Diep, N., Guha, S., & Krishnan, S. (2014) · Cancer Medicine · doi:10.1002/cam4.367 · Cited by 59
Cost of care for colorectal cancer in Ireland: a health care payer perspective
Tilson, L., Sharp, L., Usher, C., Walsh, C., Whyte, S., O'Ceilleachair, A., Stuart, C. M., Mehigan, B. J., Kennedy, M. J., Tappenden, P., et al. (2011) · The European Journal of Health Economics · doi:10.1007/s10198-011-0325-z · Cited by 58
“Radiotherapy is recommended for some rectal cancers if the clinical stage is involved, with trials indicating that preoperative, compared to postoperative, administration may improve local control and result in lower toxicity and reduced rectal cancer deaths [16, 17].”
Overview of Radiation Therapy for Treating Rectal Cancer
Kye, B., & Cho, H. (2014) · Annals of Coloproctology · doi:10.3393/ac.2014.30.4.165 · Cited by 69
“First of all, reducing tumor volume may facilitate resection and increase the likelihood of a sphincter-sparing procedure [7, 8].”
BackgroundMethodInfluentialGollins, S., Myint, A. S., Haylock, B. J., Wise, M., Saunders, M. P., Neupane, R., Essapen, S., Samuel, L. M., Dougal, M., Lloyd, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7697 · Cited by 59
Glynne‐Jones, R., Anyamene, N. A., Moran, B. J., & Harrison, M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds010 · Cited by 57
Hernando, O., López, M., Cubillo, A., Rodriguez, A., Ciérvide, R., Valero, J., Sánchez, E., Garcia-Aranda, M., Rodríguez-Pascual, J., Potdevin, G., et al. (2014) · Strahlentherapie und Onkologie · doi:10.1007/s00066-014-0650-0 · Cited by 61
Colorectal cancer in adolescents and young adults: Defining a growing threat
Levine, O. H., & Zbuk, K. M. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27941 · Cited by 61
Assumpcao, L., Choti, M. A., Gleisner, A. L., Schulick, R. D., Swartz, M., Herman, J., Gearhart, S. L., & Pawlik, T. M. (2008) · Archives of Surgery · doi:10.1001/archsurg.143.8.743 · Cited by 61
Ballonoff, A., Kavanagh, B. D., McCarter, M. D., Kane, M. A., Pearlman, N. W., Nash, R., Shah, R. J., Raben, D., & Schefter, T. E. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318161dbd3 · Cited by 59
Valentini, V., Glimelius, B. L. G., Minsky, B. D., Cutsem, E. V., Bartelink, H., Beets‐Tan, R. G. H., Gérard, J., Kosmidis, P., Påhlman, L., Picciocchi, A., et al. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.07.001 · Cited by 55
“A minority of reviewers expressed their opinion that data of the Polish trial do not support the use of preoperative chemoradiation [29], and the German trial has only seen a potential gain in a small subset of the patients [30].”
BackgroundResultGlynne‐Jones, R., Falk, S., Maughan, T., Meadows, H. M., & Sebag‐Montefiore, D. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603570 · Cited by 55
“It is also recognised that 20–40% of rectal cancer patients continue to develop distant metastases and die despite the optimal use of TME and a very low risk of local recurrence (Kapiteijn et al, 2001; Sauer et al, 2004).”
BackgroundAytaç, E., Lavery, I. C., Kalady, M. F., & Kiran, R. P. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e3182880ffa · Cited by 54
Chang, J. S., Keum, K. C., Kim, N. K., Baik, S. H., Min, B. S., Hur, H., Lee, C. G., & Koom, W. S. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31829068c5 · Cited by 57
Thomas, F., Motsinger‐Reif, A. A., Hoskins, J. M., Dvorak, A., Roy, S., Alyasiry, A., Myerson, R. J., Fleshman, J. W., Tan, B. R., & McLeod, H. L. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.442 · Cited by 58
“Pathologic downstaging (DS) or a pathologic complete response (pCR) after preoperative CRT has been correlated with improved survival, decreased recurrence and a higher rate of sphincterpreserving surgeries (Theodoropoulos et al, 2002; Valentini et al, 2002; Garcia-Aguilar et al, 2003; Crane et al, 2003b).”
BackgroundInfluentialClinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors
Lambrecht, M. L. F., & Haustermans, K. M. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.07.019 · Cited by 54
Nurkin, S. J., Kakarla, V. R., Ruiz, D. E., Cance, W. G., & Tiszenkel, H. (2013) · Colorectal Disease · doi:10.1111/codi.12248 · Cited by 54
Willett, C. G., Duda, D. G., Ancukiewicz, M., Shah, M., Czito, B. G., Bentley, R. C., Poleski, M. H., Fujita, H., Lauwers, G. Y., Carroll, M. D., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0030 · Cited by 56
Sun, Y., Xu, Z., Lin, H., Lu, X., Huang, Y., Huang, S., Wang, X., & Chi, P. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.07.022 · Cited by 62
Evolution of transanal total mesorectal excision for rectal cancer: From top to bottom
Emile, S. H., de Lacy, F. B., Keller, D. S., Martín-Pérez, B., Alrawi, S., Lacy, A. M., & Chand, M. (2018) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v10.i3.28 · Cited by 58
Tominaga, T., Akiyoshi, T., Yamamoto, N., Taguchi, S., Mori, S., Nagasaki, T., Fukunaga, Y., & Ueno, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212978 · Cited by 57
Chung, E., Lee, H. S., Cho, E., Park, E. J., Baik, S. H., Lee, K. Y., & Kang, J. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.03.014 · Cited by 58
How Reliable Is CT Scan in Staging Right Colon Cancer?
Fernandez, L. M., Parlade, A. J., Wasser, E. J., Dasilva, G., de Azevedo, R. U., Ortega, C. D., Perez, R. O., Habr‐Gama, A., Berho, M. E., & Wexner, S. D. (2019) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001387 · Cited by 54
Caudle, A. S., Kim, H. J., Tepper, J. E., O’Neil, B. H., Lange, L., Goldberg, R. M., Bernard, S. A., Calvo, B. F., & Meyers, M. O. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9873-6 · Cited by 54
“for patients with locally advanced rectal cancer and is associated with lower local recurrence rates and decreased toxicity than post-operative regimens.(6) In addition, response to neoadjuvant therapy is recognized as a valuable marker of tumor biology and prognosis in breast and esophageal cancer, as well as rectal…”
BackgroundChemoradiotherapy for Rectal Cancer — When, Why, and How?
Madoff, R. D. (2004) · New England Journal of Medicine · doi:10.1056/nejme048213 · Cited by 61
Velenik, V., Ocvirk, J., Oblak, I., & Anderluh, F. (2009) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2009.12.002 · Cited by 59
“002 6%) in patients receiving preoperative 5-FU-based chemoradiotherapy (CRT) compared with postoperative 5-FUbased CRT have also been demonstrated.(5) The addition of continuous infusion (CI) 5-FU-based chemotherapy concurrently to preoperative long-term fractionation radiation is now considered by many to be the sta…”
BackgroundDing, L., Liu, G., Zhao, B., Zhou, Y., Li, S., Zhang, Z., Guo, Y., Li, A., Lu, Y., Yao, H., et al. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000095 · Cited by 54
“[11-14] Hence, an accurate evaluation of LN metastasis is crucial to clinical decision-making Magnetic resonance imaging (MRI) is assumed to be an optimal diagnostic modality for tumor staging in rectal cancer patients due to its high soft-tissue contrast.”
BackgroundSprenger, T., Conradi, L., Beißbarth, T., Ermert, H., Homayounfar, K., Middel, P., Rüschoff, J., Wolff, H. A., Schüler, P., Ghadimi, Β. M., et al. (2012) · Cancer · doi:10.1002/cncr.27703 · Cited by 53
“To the best of our knowledge, this was the largest investigation to date of CD133 expression in rectal cancers based on a well documented patient cohort that received standardized treatment within the 2 phase III randomized German Rectal Cancer Trials.(1) We observed that 69% of all primary rectal cancers had CD133 ex…”
BackgroundMethodSelf-citationNeoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
Ferrari, L., & Fichera, A. (2015) · Gastroenterology report · doi:10.1093/gastro/gov039 · Cited by 63
Zeng, W., Liang, J., Wang, Z., Zhang, X., Hu, J., Hou, H.-R., Zhou, H.-T., & Zhou, Z. (2015) · 癌症:英文版 · doi:10.1186/s40880-015-0033-7 · Cited by 56
“Compared with surgical resection alone or postoperative CRT, preoperative CRT improves local control and increases the rate of sphincter preservation [3, 4].”
Backgroundvan der Leij, F., Elkhuizen, P. H. M., Janssen, T. M., Poortmans, P., van der Sangen, M. J. C., Scholten, A. N., van Vliet-Vroegindeweij, C., & Boersma, L. J. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.10.033 · Cited by 53
Ahmed, S., Ahmad, I., Zhu, T., Arnold, F., Anan, G. F., Sami, A., Yadav, S. K., Alvi, R., & Haider, K. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181e78815 · Cited by 53
Shaikh, I., Askari, A., Ourû, S., Warusavitarne, J. H., Athanasiou, T., & Faiz, O. D. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-2045-1 · Cited by 53
“TME with or without preoperative CRT is currently the standard of care for mid and lower third rectal cancers and has a local recurrence rate and 5-yeaar overall survival of 6–8 and 76%, respectively [4, 5].”
BackgroundMethodInfluentialDamin, D. C., & Lazzaron, A. R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i4.877 · Cited by 53
Roeder, F., Goetz, J.-M., Habl, G., Bischof, M., Krempien, R. C., Buechler, M. W., Hensley, F. W., Huber, P., Weitz, J., & Debus, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-592 · Cited by 57
“IORT: intraoperative radiation therapy, n: number of patients, R0: complete resectio disease, 5-year OS: 5-year overall survival [percentage], 5-year LC: 5-year local contr decreased local failure rates in primary rectal cancer [1,15].”
BackgroundKiran, R. P., Kirat, H. T., Burgess, A. N., Nisar, P. J., Kalady, M. F., & Lavery, I. C. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2044-1 · Cited by 53
“In patients with clinical stage T3 or T4 or node-positive rectal cancer, use of postoperative chemoradiotherapy may result in worse local control and increased toxicity compared with neoadjuvant chemoradiotherapy.(11) Thus, the current ‘‘gold standard’’ of treatment for mid to low rectal cancers that shows nodal metas…”
BackgroundElmi, A., Hedgire, S., Covarrubias, D. A., Abtahi, S. M., Hahn, P. F., & Harisinghani, M. G. (2013) · Clinical Radiology · doi:10.1016/j.crad.2013.05.094 · Cited by 53
Dolinsky, C. M., Mahmoud, N. N., Mick, R., Sun, W., Whittington, R. W., Solin, L. J., Haller, D., Giantonio, B. J., O’Dwyer, P., Rosato, E. F., et al. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20815 · Cited by 53
Erben, P., Ströbel, P., Horisberger, K., Popa, J., Bohn, B., Hanfstein, B., Kähler, G. F. B. A., Kienle, P., Post, S., Wenz, F. K., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.043 · Cited by 55
Dobie, S. A., Warren, J. L., Matthews, B. J., Schwartz, D. A., Baldwin, L., & Billingsley, K. G. (2008) · Cancer · doi:10.1002/cncr.23244 · Cited by 55
“However, this does not take into account the importance of preventing local recurrence, where the role of radiation therapy is, perhaps, most important.(33,35) Whereas some have argued that meticulous surgi-”
BackgroundResultSaigusa, S., Toiyama, Y., Tanaka, K., Yokoe, T., Okugawa, Y., Kawamoto, A., Yasuda, H., Inoue, Y., Miki, C., & Kusunoki, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0970-y · Cited by 55
Akasu, T., Takawa, M., Yamamoto, S., Ishiguro, S., Yamaguchi, T., Fujita, S., Moriya, Y., & Nakanishi, Y. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0047-3 · Cited by 54
“This is based on evidence that radiotherapy better reduces local recurrence and prolongs disease-free and overall survival when compared with surgery alone,(15,16) and that preoperative chemoradiotherapy is more effective for local control, less toxic, and more favorable for sphincter preservation than postoperative t…”
Schroeder, C., Gani, C., Lamprecht, U., von Weyhern, C. H., Weinmann, M., Bamberg, M., & Berger, B. (2012) · International Journal of Hyperthermia · doi:10.3109/02656736.2012.722263 · Cited by 55
“Preoperative 5-fluorouracil-based radiochemotherapy followed by total mesorectal excision (TME) has become a mainstay in the treatment of locally advanced rectal cancer [1].”
BackgroundMethodInfluentialShaverdian, N., Yang, Y., Hu, P., Hart, S., Sheng, K., Lamb, J., Cao, M., Agazaryan, N., Thomas, D. H., Steinberg, M. L., et al. (2017) · British Journal of Radiology · doi:10.1259/bjr.20160739 · Cited by 53
Koganemaru, S., Inoshita, N., Miura, Y., Miyama, Y., Fukui, Y., Ozaki, Y., Tomizawa, K., Hanaoka, Y., Toda, S., Suyama, K., et al. (2017) · Cancer Science · doi:10.1111/cas.13229 · Cited by 55
Moore, J., Price, T. J., Carruthers, S., Selva‐Nayagam, S., Luck, A., Thomas, M., & Hewett, P. J. (2017) · Colorectal Disease · doi:10.1111/codi.13724 · Cited by 59
Grade, M., Ghadimi, Β. M., Varma, S., Simon, R., Wangsa, D., Barenboim‐Stapleton, L., Liersch, T., Becker, H., Ried, T., & Difilippantonio, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2533 · Cited by 56
“Therefore, we complemented gene expression profiling with a comprehensive mapping of genomic imbalances in a subset of patients with rectal adenocarcinomas obtained from the German Rectal Cancer Study Group Trial (7).”
MethodSelf-citationVliegen, R. F. A., Beets‐Tan, R. G. H., Vanhauten, B., Driessen, A. L. C., Öllers, M., Kessels, A. G. H., Arens, A. M., Beets, G. L., Buijsen, J., van Baardwijk, A. A. W., et al. (2008) · Strahlentherapie und Onkologie · doi:10.1007/s00066-008-1858-7 · Cited by 57
“... FDG uptake of these small tumor nests beyond any detection level of today’s PET techniques obviously results in an underestimation of the actual tumor volume and, therefore, an overestimation of anatomic tumor response as observed by us. This finding is supported by a recent PET study of Capirci et al. showing sma…”
BackgroundResultSouth Australian clinical registry for metastatic colorectal cancer
Neo, E. L., Beeke, C., Price, T. J., Maddern, G. J., Karapetis, C. S., Luke, C., Roder, D. M., & Padbury, R. (2010) · ANZ Journal of Surgery · doi:10.1111/j.1445-2197.2010.05589.x · Cited by 52
“For rectal cancer, we see not only similar chemotherapy trends, but also the greater use of preoperative radiotherapy rather than postoperative radiotherapy, in keeping with the current evidence-based recommendations.(3,11) The criteria for hepatic resection of colorectal liver metastases have expanded over the past 1…”
ResultMorbidity after Closure of a Defunctioning Loop Ileostomy
D’Haeninck, A., Wolthuis, A. M., PENNINCKX, F. M., D’Hondt, M. A., & D’Hoore, A. J. L. (2011) · Acta chirurgica Belgica · doi:10.1080/00015458.2011.11680724 · Cited by 52
Indian Council of Medical Research consensus document for the management of colorectal cancer
Sirohi, B., Shrikhande, S. V., Perakath, B., Raghunandharao, D., Julka, P. K., Lele, V. R., Chaturvedi, A., Nandakumar, A., Ramadwar, M. S., Bhatia, V., et al. (2014) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.142031 · Cited by 54
“For T3/T4lesions, node positive lesions, where the CRM is threatened, patients can be offered long-course neoadjuvant chemo-radiotherapy (NACTRT) to decrease the local recurrence rate, improve disease-free survival and increase sphincter preservation rates.[16] Standard NACTRT refers to a dose of 46-50.”
BackgroundChen, Y., Wei, M., Wang, C.-W., Lee, H.-W., Pan, S., Gao, M., Kuo, S., Cheng, A., & Teng, C. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.015 · Cited by 55
Wan, J., Gai, Y., Li, G., Tao, Z., & Zhang, Z. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.09.012 · Cited by 52
Ceelen, W. P., Smeets, P., Backes, W. H., Damme, N. V., Boterberg, T., Demetter, P., Bouckenooghe, I., Visschere, M. D., Peeters, M., & Pattyn, P. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.10.026 · Cited by 53
Ishibe, A., Ota, M., Watanabe, J., Suwa, Y., Suzuki, S., Kanazawa, A., Watanabe, K., Ichikawa, Y., Kunisaki, C., & Endo, I. (2015) · World Journal of Surgery · doi:10.1007/s00268-015-3299-7 · Cited by 55
“In Western countries, therefore, TME combined with radiotherapy is the standard treatment for rectal cancer [3, 4].”
BackgroundKreis, M. E., Ruppert, R., Ptok, H., Straßburg, J., Brosi, P., Lewin, A., Schön, M. R., Sauer, J., Junginger, T., Merkel, S., et al. (2015) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-015-3011-0 · Cited by 56
Raldow, A. C., Chen, A. B., Russell, M. M., Lee, P. P., Hong, T. S., Ryan, D. P., Cusack, J. C., & Wo, J. Y.-L. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2249 · Cited by 52
Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
Papaccio, F., Roselló, S., Huerta, M., Gambardella, V., Tarazona, N., Fleitas, T., Roda, D., & Cervantes, A. M. R. (2020) · Cancers · doi:10.3390/cancers12123611 · Cited by 56
“in the New England Journal of Medicine [4], which confirmed the value of preoperative chemoradiation in reducing local relapses vs.”
BackgroundInfluentialNeoadjuvant radiation for clinical T4 colon cancer: A potential improvement to overall survival
Hawkins, A. T., Ford, M. M., Geiger, T. M., Hopkins, M. B., Kachnic, L. A., Muldoon, R. L., & Glasgow, S. C. (2018) · Surgery · doi:10.1016/j.surg.2018.06.015 · Cited by 54
Schaap, D. P., Voogt, E. L. K., Burger, J. W. A., Cnossen, J. S., Creemers, G., van Lijnschoten, I. G., Nieuwenhuijzen, G. A. P., Rutten, H. J. T., Gooszen, A. W., Nederend, J., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.06.013 · Cited by 54
Park, M., Kwon, J., Kong, J., Moon, S. M., Cho, S., Yang, K. Y., Jang, W. I., Kim, M., Kim, Y., & Shin, U. S. (2021) · Cancers · doi:10.3390/cancers13153760 · Cited by 54
“Since the German trial of 2004, neoadjuvant chemoradiation therapy (NCRT), followed by radical surgery with total mesorectal excision, has been a standard treatment for locally advanced rectal cancer without metastasis [1,2].”
BackgroundNeoadjuvant-intensified treatment for rectal cancer: Time to change?
Musio, D., Felice, F. D., Bulzonetti, N., Guarnaccia, R., Caiazzo, R., Bangrazi, C., Raffetto, N., & Tombolini, V. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i20.3052 · Cited by 54
Metadata
- Authors
- Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., & Raab, R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Leipzig University (DE)
- University of Rostock (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital of the Brothers of St. John of God (AT)
- Klinikum Klagenfurt (AT)
- University of Göttingen (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Oldenburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1731-1740
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125452425
- Cited by
- 6,050
- References
- 19
- Citations by year
- 2026: 178 · 2025: 205 · 2024: 232 · 2023: 275 · 2022: 310 · 2021: 324 · 2020: 322 · 2019: 321 · 2018: 305 · 2017: 298 · 2016: 291 · 2015: 348 · 2014: 340 · 2013: 333 · 2012: 346
- FWCI
- 82.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- rectal cancer, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, postoperative chemoradiotherapy, neoadjuvant therapy, adjuvant therapy, 5-fluorouracil, boost radiotherapy, local recurrence, overall survival, treatment toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Postoperative Care, Postoperative Complications, Preoperative Care, Quality Control, Radiotherapy, Rectal Neoplasms, Incidence, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.